Immunic, Inc.

NASDAQ:IMUX

Biotechnology

Healthcare
$7.52 -0.28%

-$0.04 today

Market cap
$102.61M
Beta
1.39
P/E (TTM)
-4.1
EPS (TTM)
-$3.46
52W Low $5.06High $15.77

Volume 0.17M

Average 0.27M

IMUX Total Non-current Assets

All assets not expected to be converted to cash within one year.

Immunic, Inc.NASDAQ: IMUX

Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026

Total non-current assets falls 36.2% from a year ago

Total non-current assets stood at $983K at the end of Q1 FY2026, down 36.2% from a year earlier and down 16.9% from the prior quarter. Over 3 fiscal years it compounded at -14.4% a year.

Context

  • Total non-current assets amounted to 0.5% of total assets at the end of Q1 FY2026, down 7.0 pp from a year earlier.
  • Total non-current assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current assets keeps falling in the next quarterly balance sheet after a -36.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$983K-16.9% QoQ
Last fiscal yearDec 2025
$1.18M-23.0% YoY
Year agoMar 2025
$1.54M-36.2% since
Total Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.2%——
1 year-23.0%——
3-year CAGR-14.4%——
5-year CAGR——
10-year CAGR——

Total Non-current Assets history

USD · from the balance sheet

Latest · FY2025
1.18M USD
Year-over-year change
-23.0%
4-year CAGR
-56.8%

Total Non-current Assets vs competitors

How IMUX compares with its peers on the latest reported figures

  • IMUX's Mar 2026 total non-current assets of $983K is the 6th highest of the 9 companies compared; the peer median is $18.96M.
  • Its year-over-year change of -36.2% is the 5th highest of 9, against a peer median of -35.9%.
  • Total non-current assets amounts to 0.5% of total assets for IMUX, versus a peer median of 12.6%.
IMUX Competitors Peer median
Total Non-current Assets for IMUX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CBUSCibus, Inc.Mar 2026$291.13M -5.8%+152.1%89.8%
TCRXTScan Therapeutics, Inc.Mar 2026$69.23M -11.1%-1.5%34.3%
VXRTVaxart, Inc.Mar 2026$48.35M -49.6%-2.8%26.9%
ACETAdicet Bio, Inc.Mar 2026$29.31M -22.3%-23.3%17.3%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$8.61M -65.6%-42.6%8.0%
IMUXImmunic, Inc.Mar 2026$983K -36.2%-14.4%0.5%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$782K -89.0%-61.4%0.8%
BMEABiomea Fusion, Inc.Mar 2026$67K -99.4%-64.3%0.1%
RLMDRelmada Therapeutics, Inc.Mar 2026$19.5K -11.3%-17.6%0.0%
Peer median (excluding IMUX) $18.96M-35.9%-20.5%12.6%

Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents86.86M106.75M46.67M35.67M15.48M
Short-term Investments09.63M000
Net Receivables2.15M296K703K684K4.12M
Inventory05.61M000
Other Current Assets1.12M3.59M2.84M1.11M1.2M
Total Current Assets104.99M125.86M52.53M39.33M22.87M
Property, Plant & Equipment (Net)1.1M1.85M1.77M1.54M1.18M
Goodwill32.97M0000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets42K43K000
Total Non-current Assets34.11M1.89M1.77M1.54M1.18M
Total Assets139.1M127.75M54.3M40.87M24.05M
Account Payables3.5M4.28M5.1M7.85M10.14M
Short-term Debt0000470K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities851K7.34M17.48M676K20.01M
Total Current Liabilities11.4M13.08M24.73M22.18M30.62M
Long-term Debt0000107K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0000(107K)
Total Non-current Liabilities584K992K639K264K107K
Total Liabilities11.99M14.07M25.37M22.44M30.73M
Common Stock3K4K4K8K9K
Retained Earnings(196.87M)(317.28M)(410.89M)(511.4M)(608.57M)
Accumulated OCI(252K)3.04M3.76M4.21M2.65M
Other Stockholders Equity00000
Minority Interest00000
Total Equity127.12M113.68M28.93M18.43M(6.67M)
Total Debt992K1.56M1.33M1M684K
Net Debt(85.87M)(105.18M)(45.34M)(34.66M)(14.8M)

Immunic, Inc.

NASDAQ:IMUX

Intrinsic Alpha fair value

Locked

Current Price

$7.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.